Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation

Mayo Clinic

Status: Completed

Conditions: Liver Transplant Surgery

Treatments: Other: TetraGraph on non-dominant hand; Other: TetraGraph on dominant hand

Study type: Observational

Funder types: Other

Identifiers

NCT05216991

21-011838

Details and patient eligibility

About

The purpose of this research is to estimate the frequency of postoperative lasting muscle weakness in patients receiving Sugammadex after undergoing liver transplant surgery by using electromyographic device (EMG), such as TetraGraph.

Enrollment: 97 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients willing to participate and provide an informed consent.
• Patients undergoing primary liver transplantation.

Exclusion criteria

• Patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
• Patients with systemic neuromuscular diseases such as myasthenia gravis.
• Patients with a known history of cerebrovascular accident (CVA).
• Patients undergoing repeat liver transplantation or concomitant pancreas/kidney transplantation at the time of liver transplantation.
• Patients admitted to the intensive care unit prior to liver transplantation.

Trial design

97 participants in 2 patient groups

TetraGraph monitoring on dominant hand

Description:

Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care

Treatment:

Other: TetraGraph on dominant hand

TetraGraph monitoring on non-dominant hand

Description:

Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care

Treatment:

Other: TetraGraph on non-dominant hand